ARVN News and Press, Arvinas Inc. From 12/05/23

NEW HAVEN, Conn., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that a conference call and webcast will be held with executives from Arvinas and Pfizer Inc...

– Overall response rate of 42% and median progression-free survival of 11.1 months in heavily pre-treated patients (after 11 months median follow-up time and based on 48% of events) demonstrates the potential of vepdegestrant in combination with palbociclib (IBRANCE ® ) – ...

-- Six abstracts have been accepted for presentation, including updated data on vepdegestrant alone and in combination with palbociclib (IBRANCE ® ) -- NEW HAVEN, Conn. and NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today ...

2023-11-27 07:40:37 ET More on Arvinas Arvinas: Protein Degradation Pioneer Presents An Intriguing Speculative Buy Opportunity Arvinas' Potential In Treating ER+, HER2- Breast Cancer Arvinas GAAP EPS of -$1.18 beats by $0.39, revenue of $34.6M misses by $5.45M ...

NEW HAVEN, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered into a securities purchase agreement with a select group of instit...

2023-11-24 02:56:01 ET Summary Arvinas is a leading company in developing protein degraders, with a depressed share price, drugs in advanced study phases, and ample cash reserves. Arvinas is focused on oncology, particularly breast and prostate cancer, setting it apart from compet...

2023-11-22 09:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-11-08 10:14:06 ET More on Arvinas Arvinas' Potential In Treating ER+, HER2- Breast Cancer Arvinas GAAP EPS of -$1.18 beats by $0.39, revenue of $34.6M misses by $5.45M For further details see: Arvinas files an automatic mixed securities shelf

Arvinas Inc. (ARVN) is expected to report $-1.52 for Q3 2023

2023-11-07 07:59:53 ET More on Arvinas Arvinas' Potential In Treating ER+, HER2- Breast Cancer Seeking Alpha’s Quant Rating on Arvinas Historical earnings data for Arvinas Financial information for Arvinas For further details see: Arvinas G...